Navigating Immune-Related Adverse Events With Nivolumab in Upper GI Cancer
Experts discuss key immune-related adverse events (irAEs) to monitor in patients receiving nivolumab, how to differentiate these from disease-related symptoms, and how to manage moderate to severe irAEs, including factors that determine whether immunotherapy should be paused or discontinued.
Video content above is prompted by the following:
• What are the key irAEs to monitor in patients receiving nivolumab, and how do you differentiate these from disease-related symptoms ?
• How do you approach the management of moderate to severe irAEs, and what factors determine whether immunotherapy should be paused or discontinued?
Recent Videos
Related Content
